Screener
BridgeBio Pharma BBIO Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 1,241,306 | 797,749 |
| Equity method investments | 61,529 | 79,972 |
| Property and equipment, net | 4,941 | 5,366 |
| Operating lease right-of-use assets | 17,226 | 8,149 |
| Intangible assets, net | 27,359 | 28,077 |
| Other assets | 18,620 | 16,712 |
| Total assets | $1,370,981 | $936,025 |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's operating lease ROU assets?
- BridgeBio Pharma (BBIO) reported operating lease ROU assets of $17.23M in Q1 2026.
- How has BridgeBio Pharma's operating lease ROU assets changed year-over-year?
- BridgeBio Pharma's operating lease ROU assets increased by 140.4% year-over-year, from $7.17M to $17.23M.
- What is the long-term trend for BridgeBio Pharma's operating lease ROU assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease ROU assets has grown at a -13.2% compound annual growth rate (CAGR), from $16.51M to $8.15M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about BridgeBio Pharma's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude